Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104500 · ClinicalTrials.gov registry record · Phase 3
VK2735 for Weight Management Phase 3
A Phase 3 study of Weight Loss, sponsored by Viking Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 4,500
- Enrollment target
- 20
- Study locations
NCT07104500 is a Phase 3 study of Weight Loss that is active but no longer recruiting, run by Viking Therapeutics. The registered enrollment target is 4,500 participants, above the 1,463-participant average among 116 other Weight Loss trials with a reported enrollment target (208% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT07104500, a Phase 3 study of Weight Loss, is active but no longer recruiting, sponsored by Viking Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 4,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Conditions Studied
Interventions
- DRUG VK2735
Study Locations (20)
California
- Viking Clinical Site #1071 - Chula Vista
- Viking Clinical Site #1070 - Escondido
- Viking Clinical Site #1054 - Huntington Park
- Viking Clinical Site #1014 - Lake Forest
- Viking Clinical Site #1129 - Lemon Grove
- Viking Clinical Site #1051 - Lincoln
- Viking Clinical Site #1050 - Long Beach
- Viking Clinical Site #1055 - Los Angeles
- Viking Clinical Site #1078 - Manteca
- Viking Clinical Site #1053 - Montclair
Arizona
- Viking Clinical Site #1005 - Chandler
- Viking Clinical Site #1017 - Flagstaff
- Viking Clinical Site #1018 - Peoria
- Viking Clinical Site #1135 - Scottsdale
- Viking Clinical Site #1019 - Tucson
Alabama
- Viking Clinical Site #1037 - Birmingham
- Viking Clinical Site #1064 - Birmingham
- Viking Clinical Site #1128 - Huntsville
- Viking Clinical Site #1081 - Mobile
Arkansas
- Viking Clinical Site #1036 - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,500 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07104500
The ClinicalTrials.gov registry entry for NCT07104500 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 4,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,463-participant average among 116 other Weight Loss trials with a reported enrollment target (208% higher). The listed sponsor is Viking Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Weight Loss appearing as the primary indexed condition, and to 1 intervention - of which VK2735 is the first listed.
NCT07104500 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT07104500 about?
NCT07104500 is a clinical study titled "VK2735 for Weight Management Phase 3". This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27...
What is the current status of trial NCT07104500?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 4,500 participants. The study started on 2025-06-23. Estimated completion is 2027-08-01.
What conditions does trial NCT07104500 study?
This clinical trial studies the following conditions: Weight Loss.
What interventions are being tested in trial NCT07104500?
The interventions under investigation include: VK2735 (DRUG).
Who is sponsoring clinical trial NCT07104500?
This trial is sponsored by Viking Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104500 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
RECRUITING · Phase 3
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
RECRUITING
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.